SE0000307D0 - Method and formulation for treatment of vasoconstriction - Google Patents

Method and formulation for treatment of vasoconstriction

Info

Publication number
SE0000307D0
SE0000307D0 SE0000307A SE0000307A SE0000307D0 SE 0000307 D0 SE0000307 D0 SE 0000307D0 SE 0000307 A SE0000307 A SE 0000307A SE 0000307 A SE0000307 A SE 0000307A SE 0000307 D0 SE0000307 D0 SE 0000307D0
Authority
SE
Sweden
Prior art keywords
vasoconstriction
formulation
treatment
compositions
precursors
Prior art date
Application number
SE0000307A
Other languages
Swedish (sv)
Inventor
Ralph A Schmid
Gabriele Schoedon
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Priority to SE0000307A priority Critical patent/SE0000307D0/en
Publication of SE0000307D0 publication Critical patent/SE0000307D0/en
Priority to PCT/CH2001/000062 priority patent/WO2001056551A2/en
Priority to AU2001226609A priority patent/AU2001226609A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compositions and methods useful for achieving therapeutic effects such as the prevention of vasoconstriction and improvement of the preservation and survival of a transplanted organ. More specifically, the compositions exhibit synergy and comprise amounts of two therapeutic agents selected from the group consisting of BH4 and its precursors , on the one hand and membrane permeable cGMP analogues on the other.
SE0000307A 2000-01-31 2000-01-31 Method and formulation for treatment of vasoconstriction SE0000307D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0000307A SE0000307D0 (en) 2000-01-31 2000-01-31 Method and formulation for treatment of vasoconstriction
PCT/CH2001/000062 WO2001056551A2 (en) 2000-01-31 2001-01-26 Method and formulation for treatment of vasoconstriction
AU2001226609A AU2001226609A1 (en) 2000-01-31 2001-01-26 Method and formulation for treatment of vasoconstriction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0000307A SE0000307D0 (en) 2000-01-31 2000-01-31 Method and formulation for treatment of vasoconstriction

Publications (1)

Publication Number Publication Date
SE0000307D0 true SE0000307D0 (en) 2000-01-31

Family

ID=20278294

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0000307A SE0000307D0 (en) 2000-01-31 2000-01-31 Method and formulation for treatment of vasoconstriction

Country Status (3)

Country Link
AU (1) AU2001226609A1 (en)
SE (1) SE0000307D0 (en)
WO (1) WO2001056551A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018620A2 (en) * 2003-08-26 2005-03-03 Cell Center Cologne Gmbh Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
CN1871011A (en) * 2003-10-31 2006-11-29 奥坦纳医药公司 Use of BH4 for the treatment of respiratory diseases
AU2004291149C1 (en) 2003-11-17 2021-01-21 Biomarin Pharmaceutical Inc. Methods and Compositions for the Treatment of Metabolic Disorders
EP1940392A2 (en) * 2005-05-11 2008-07-09 Nycomed GmbH Combination of the pde4 inhibitor and a tetrahydrobiopterin derivative
EP1965803A1 (en) * 2005-12-05 2008-09-10 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of disease
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
BR112018075689A2 (en) * 2016-06-13 2019-04-02 Meharry Medical College Nitric oxide synthase pathway modulation for oral health

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation

Also Published As

Publication number Publication date
AU2001226609A1 (en) 2001-08-14
WO2001056551A3 (en) 2002-07-11
WO2001056551A2 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
CO5700767A2 (en) TRANSPLANT REJECTION TREATMENT PROCEDURE
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
DE60112609D1 (en) Pyrazolopyridine
AP2002002458A0 (en) Compounds for the treatment of ischemia.
DK1299348T3 (en) Compounds and compositions for delivery of active agents
YU46200A (en) N(substituted five-membered di-or triaza diunsaturated ring) carbonyl/ guanidine derivatives for the treatment of ischemia
DE602005021770D1 (en) INDOLE-1-YL-ACETIC DERIVATIVES
RS49756B (en) Use of xenon for preparing a pharmaceutical preparation for treating neurointoxications
ECSP045004A (en) INHIBITORS OF THE 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3 FOR THE TREATMENT OF DEPENDING ANDROGEN DISEASES
NO20064584L (en) Tetrahydropyridoindolderivater
ATE218581T1 (en) CYCLOSPORINE DERIVATIVE, PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION
DE60112330D1 (en) Pyrazolopyridinderivate
YU87202A (en) Arylmethylamine derivatives for use as tryptase inhibitors
WO2002043706A3 (en) Prolamin-based sustained-release compositions and delayed-onset compositions
SE0000307D0 (en) Method and formulation for treatment of vasoconstriction
RS50148B (en) Use of docetaxel for treating hepatocellular carcinoma
ATE324112T1 (en) TOPICAL TREATMENT FOR MASTALGIA
DK1307445T3 (en) Benzofuran derivatives and their use as antibacterial agents
TR200402070T4 (en) Cyclobutene-dione derivatives and their use in the treatment of arteriosclerosis
RS20060154A (en) Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
MXPA06007007A (en) Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours.
TR200302134T4 (en) Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and / or physiologically acceptable salts thereof as anti-cancer agents.
UY26648A1 (en) VASOPEPTIDASE INHIBITORS TO TREAT ISOLATED SYSTOLIC HYPERTENSION
NO20033273D0 (en) Use of (R) -ibuprofen-methanesulfonamide and its salts for treatment and prevention of rejection of transplanted organs
HRP20070441T3 (en) Pharmaceutical combination for the treatment of spasticity and/or pain